OrganoTherapeutics

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Founded in July 2019 by Prof. Dr. Jens Schwamborn and Dr. Javier Jarazo, the Luxembourgish biotech company OrganoTherapeutics S.a.r.l. (OT) makes use of a proprietary human-specific 3D in vitro model, the so-called midbrain organoids, for the discovery and development of effective drug candidates, which target neurodegeneration in Parkinson`s disease (PD) patients. The business strategy of OT is based on three pillars: I) usage of the midbrain organoids for own drug development, II) usage of midbrain organoids for joint drug development campaigns with other biotech & pharma companies and II) selling of midbrain organoids as product for R&D.
Speaker
photo
Prof. Dr.
OrganoTherapeutics